US20060004185A1 - Peptide antibiotics and peptide intermediates for their prepartion - Google Patents

Peptide antibiotics and peptide intermediates for their prepartion Download PDF

Info

Publication number
US20060004185A1
US20060004185A1 US10/881,160 US88116004A US2006004185A1 US 20060004185 A1 US20060004185 A1 US 20060004185A1 US 88116004 A US88116004 A US 88116004A US 2006004185 A1 US2006004185 A1 US 2006004185A1
Authority
US
United States
Prior art keywords
dab
peptide
fmoc
thr
protected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US10/881,160
Other languages
English (en)
Inventor
Richard Leese
Noreen Francis
William Curran
Donald Borders
Howard Jarolmen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosource Pharm Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/881,160 priority Critical patent/US20060004185A1/en
Assigned to BIOSOURCE PHARM, INC. reassignment BIOSOURCE PHARM, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BORDERS, DONALD B., CURRAN, WILLIAM V., FRANCIS, NORMAN D., JAROLMEN, HOWARD, LEESE, RICHARD A.
Priority to RU2007103811/04A priority patent/RU2428429C2/ru
Priority to NZ579261A priority patent/NZ579261A/en
Priority to AU2005326770A priority patent/AU2005326770B2/en
Priority to US11/630,847 priority patent/US8889826B2/en
Priority to CA002571944A priority patent/CA2571944A1/en
Priority to BRPI0512941-9A priority patent/BRPI0512941A/pt
Priority to NZ552730A priority patent/NZ552730A/en
Priority to EP10184953A priority patent/EP2332965A1/en
Priority to MXPA06015239A priority patent/MXPA06015239A/es
Priority to KR1020077002649A priority patent/KR20070047770A/ko
Priority to PCT/US2005/023343 priority patent/WO2006083317A2/en
Priority to JP2007519447A priority patent/JP2008505858A/ja
Priority to EP05856867A priority patent/EP1761554A2/en
Priority to CNA2005800294199A priority patent/CN101010336A/zh
Publication of US20060004185A1 publication Critical patent/US20060004185A1/en
Priority to ZA200610818A priority patent/ZA200610818B/en
Priority to IL180458A priority patent/IL180458A0/en
Priority to NO20070563A priority patent/NO20070563L/no
Priority to RU2011115077/04A priority patent/RU2011115077A/ru
Priority to JP2011168634A priority patent/JP2011256189A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention relates to methods for preparing novel protected peptide intermediates from polymyxin B or from related lipopeptide antibiotics, which are used to readily prepare new families of antibiotics that have potent activity against gram-negative and gram-positive bacteria.
  • Polymyxin B and the related colistin have been used in humans but their use has been previously restricted because of toxicity and the availability of the other less toxic and previously effective antibiotics cited above (Ref. 1). Polymyxin B and colistin are usually administered by intravenous or intramuscular dosing.
  • Colistimethate sodium is a water soluble salt of colistin/formaldehyde/bisulfite and has been of particular therapeutic value in acute and chronic urinary tract infections caused by strains of Pseudomonas aeruginosa (PDR Generics).
  • Polymyxin B sulfate is the drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of P. aeruginosa (PDR Generics). Aerosolized polymyxin B is an important component of therapeutic regimens used in the management of pseudomonal lung infections, characteristically found in cystic fibrosis (Ref. 2). Some renal toxicity was observed with recommended dosing of polymyxin B in patients.
  • the total synthesis of polymyxin B and four analogs was accomplished by a combination of solid phase peptide syntheses to obtain linear structures followed by removal from the resin and condensation in solution at high dilution to obtain the cyclic peptides (Ref. 7).
  • the derivatives were less active than polymyxin B and one compound contained an Fmoc group in the terminal acyl position.
  • a more recent total synthesis of polymyxin B and a few closely related compounds was accomplished only by solid phase peptide synthesis (Ref. 15). Both of these solid phase total synthetic approaches can provide new derivatives of polymyxin but these methods appear limited compared to the methods of the present invention.
  • the quantities of antibiotic produced are small and require large amounts of amino acid precursors.
  • a primary object of the present invention is to provide potent and effective antibiotics for treating gram-negative bacteria, without limiting use because of toxicity.
  • a further object of the present invention is to provide intermediates from polymyxin B or related lipopeptide antibiotics which can be used to prepare new families of antibiotics having potent activity against gram-negative and gram-positive bacteria.
  • polymyxin B protected form of polymyxin B is polyanionic, water soluble as a salt, and readily reacts in aqueous solution with a particular deacylase enzyme produced by Actinoplanes utahensis. It has not been found to react with polymyxin deacylase or the other enzymes commonly used to produce the nonapeptides of polymyxin or colistin (Ref. 11).
  • the deacylated protected polymyxin peptide designated the protected PBpeptide-3, has three amino acids in the side chain.
  • the enzyme from Actinoplanes utahensis can be used as the whole broth from the fermentation, the washed cells, or a water-solubilized preparation.
  • the water-solubilized enzyme preparation was obtained by a basic extraction of the washed cells and then the clear extract was adjusted to pH 7-8. This enzyme preparation is the easiest to use, can be freeze-dried to a powder form, and is the most efficient.
  • This invention includes methods for preparing four novel protected peptide intermediates from polymyxin B or related lipopeptide antibiotics that are used to prepare new families of anti-biotics which have potent activity against gram-negative, and in some cases gram-positive bacteria.
  • Polymyxin B can be isolated from the fermentation of Bacillus polymyxa according to procedures described in Ref. 14. New antibiotics can be prepared from not only polymyxin B but also from related antibiotics such as other polymyxins, colistin, circulin, and octapeptin (EM49, Ref. 13) by these procedures.
  • the five basic groups of polymyxin B are protected with a sulfonic acid derivative of 9-fluorenylmethoxycarbonyl, as shown in the following structures of the protecting groups:
  • the deacylated protected polymyxin peptide designated the protected PBpeptide-3, has three amino acids in the side chain.
  • the enzyme preparation that deacylates the protected polymyxin B can be obtained as a water soluble freeze-dried powder which is relatively stable.
  • the preparation of this enzyme is easily accomplished and requires a unique process involving fermentation of Actinoplanes utahensis, separating the cells from the fermentation, washing the cells with water, extracting the cells with a basic buffer at pH 10 for about 20 minutes, adjusting the extract to pH 7-8 and freeze-drying.
  • the powdered form of the enzyme resulting from this process is relatively stable and can be readily re-dissolved in water for use. Further purification can be obtained by gel filtration chromatography.
  • This enzyme readily deacylates the N-[(2-Sulfo)-9-fluorenlymethoxycarbonyl)] 5 polymyxin B to obtain the protected polymyxin B peptide.
  • This soluble enzyme was also effective in current studies for deacylation of N-fluorenlymethoxycarbonyl) amphomycin, laspartomycin, and N-fluorenlymethoxycarbonyl)-A21978C which are not polymyxin.
  • polymyxin-type antibiotics such as the polymyxins, octapeptins, colistin, or circulins
  • the procedures described above can be used to prepare protected intermediates selected from a group consisting of the following or their corresponding salts:
  • the present invention describes semisynthetic antimicrobial cyclopeptides and their methods of preparation from the PBpeptides or other related peptides derived from collistin, circulin or octapeptin.
  • This invention describes four different PBpeptide intermediates which can be elaborated further to afford the new antimicrobial derivatives, illustrated in the following embodiment:
  • Each of these novel PBpeptide intermediates can be used to make new series of potent antibacterial antibiotics by the general procedures described.
  • the desired acids were converted to activated species and then coupled to the protected intermediate PBpeptides and deprotected to give the new antibiotics as represented by compounds 1, 2, 6, 7, 11 and 12 in Table 1.
  • the protected intermediate PBpeptides could also be acylated directly with alkyl or aromatic isocyanates or isothiocyanates to give the corresponding ureas and thioureas and the products deprotected to give other new series of antibiotics as represented by compounds 3-5.
  • the biological activities of some of the new antibiotics prepared from PBpeptides by these procedures are given in Table 1.
  • the HSO 3 Fmoc or other acidic Fmoc protected peptides from colistin (Cpeptides), circulin A (CA peptides), octapeptin B (Obpeptin), octapeptin C (OCpeptides), polymyxin A (PApeptides), and polymyxin D (PDpeptides) can be derivatized to give new antibiotics and new antibiotic prodrugs by the described procedures.
  • the new HSO 3 Fmoc derivatives of our new antibiotics are listed in Table 2, and would all be expected to be pro-drugs for their corresponding antibiotics.
  • the pro-drug may act as a slow release mechanism for the pharmacokinetics of the antibiotic.
  • Polymyxin B sulfate (1.0 g., 0.841 mmol.) was dissolved in a solution of 25 ml., saturated sodium bicarbonate, 25 ml. of water and 25 ml. of tetrahydrofuran.
  • a solution of (2-sulfo)-9-fluorenylmethoxy-N-hydroxysuccinimide (2.0 g., 4.8 mmol.) in 25 ml. of tetrahydrofuran was added in several portions over 45 min.
  • the reaction mixture was stirred at room temperature over night and diluted with 50 ml. of water, then acidified with 25 ml of 6N hydrochloric acid to give an oily precipitate.
  • the deacylase is produced by culturing Actinoplanes utahensis NRRL 12052 under submerged aerobic fermentation conditions. Because single-colony isolates from a lyophile of the culture were heterogeneous for both morphology and enzyme production capability, selections were made to recover a stable, high-producing variant. Initially, multiple fermentations were carried out using inocula prepared from strain 12052. Vegetative growth from the flask yielding the best deacylating activity was plated on a differential agar (CM). Colonies were then selected for further evaluation. Generally, small colonies were better enzyme producers than the large colony types. Isolate No. 18 was selected as a small colony type and shown to be the best deacylase producer of all colonies selected.
  • CM differential agar
  • CM agar contained corn steep liquor 0.5%, Bacto peptone 0.5%, soluble starch 1.0%, NaCl 0.05%, CaCl 2 .2H 2 O 0.05% and Bacto agar 2.0%.
  • the fermentation protocol employed is known (17).
  • a high-producing, natural variant was used in this invention.
  • the resulting mycelial suspension was transferred into 50 mL of PM3 medium in a 250-mL Erlenmeyer flask.
  • This medium contained sucrose 2.0%, peanut meal 1.0%, K 2 HPO 4 0.12%, KH 2 PO 4 0.05% and MgSO 4 .7H 2 O 0.025% in tap water.
  • the flask was incubated at a temperature of 30° C. for a period of 60 to 90 hrs.
  • the harvest time was determined by an assay which involved HPLC analyses of the deacylation of (2-Sulfo-9-fluorenlymethoxycarbonyl)] 5 polymyxin B by the whole broth at different times during the fermentation.
  • Precipitation Method Cells from 450 ml deacylase enzyme were washed 3 ⁇ with water, then brought back to original volume with 0.02 M ammonium phosphate buffer and adjusted to pH 8.0. N-[(2-Sulfo)-9-fluorenlymethoxycarbonyl)] 5 -polymyxin B, 897 mg, was added and the mixture was placed on a shaker at 174 rpm and maintained at 30° C. After five hours the mixture was separated by centrifuging. The clear decant was adjusted to pH 2.3 with 1 N HCl to induce precipitation and allowed to stand at room temperature.
  • the precipitate was separated from the mixture, slurried in 80 ml water, adjusted to pH 6.5 to obtain a clear solution, and freeze-dried to obtain 400 mg of tan powder, the semi-purified salt of the protected peptide, N-[(2-Sulfo)-9-fluorenlymethoxycarbonyl] 5 -polymyxin peptide [(NaSO 3 -Fmoc) 5 -PBP-3].
  • the cells were extracted with methanol/water to obtain additional material.
  • Resin Method Cells from 1 liter deacylase enzyme were washed 3 ⁇ with water, brought back to original volume with 0.02 M ammonium phosphate buffer, and combined with 2.0 g of N-(2-sulfo)-9-fluorenlymethoxycarbonyl)] 5 -polymyxin B. The mixture was placed on a shaker at 175 rpm and maintained at 30° C. for 17 hours. The mixture was then separated by centrifuge and the decant was combined with 20 ml of Amberchrom® CG-161m resin. The resin was washed with 150 ml water, 100 ml 10% CH 3 CN:H 2 O (3 ⁇ ), and 100 ml 20% CH 3 CN:H 2 O (2 ⁇ ).
  • the peptide was then eluted 2 ⁇ with 30% CH 3 CN:H 2 O, evaporated to remove CH 3 CN, and freeze-dried to obtain 283 mg powder, the purified peptide.
  • the remaining peptide was then eluted 3 ⁇ with 100 ml 50% CH 3 CN:H 2 O, which were combined evaporated and freeze-dried to obtain 460 mg powder, the purified peptide.
  • the remaining peptide was extracted from the cells 6 ⁇ with MeOH: H 2 O, 100 ml each. The extracts were combined, brought to four liters with water, adjusted to pH 2.1 with sulfuric acid and combined with Amberchrom® CG-161m resin.
  • the resin was rinsed with water and then the peptide was eluted with 100 ml 35% CH 3 CN:H 2 O, which was evaporated and freeze-dried to obtain 94 mg purified peptide. The remaining peptide was eluted with 50% CH 3 CN:H 2 O, evaporated to remove CH 3 CN, and freeze-dried to obtain 539 mg of the purified peptide.
  • the [(2-Sulfo)-9-fluorenlymethoxycarbonyl)] 5— polymyxin B peptide[(HSO 3 -Fmoc) 5 -PBP-3)] was isolated from these procedures as tan powder, C 122 H 134 N 16 O 37 S 5 .
  • N-phenylthiocarbamyl-(NaSO 3 -Fmoc) 5 -PBP-3 was dissolved in 0.20 mL dimethylformamide (DMF), 0.010 mL piperidine was added and stirred at RT for 60 min.
  • the reaction mixture was diluted with 4 mL 0.10M ammonium acetate-0.050M acetic acid (pH 5.05) and 0.006 mL acetic acid and 4 mL MeOH.
  • the clear solution was applied to a CM-Sepharose® column (10 ⁇ 20 mm, ca. 2 mL volume) which had been conditioned with 50% MeOH 0.05M in ammonium acetate buffer at pH 5.0.
  • the sample-loaded column was rinsed with 4 mL 50% MeOH-0.05M ammonium acetate pH 5.0 then with 4 mL 0.05M ammonium acetate pH 5.0 buffer.
  • Product was eluted with 8 mL of 0.27 M sodium sulfate at pH 2.3.
  • the product was further purified by application onto a 0.5 g styrene-divinylbenzene cartridge (EnviChrom-P) which was eluted with incrementally increasing concentrations of CH 3 CN 0.05M in pH 2.3 sodium sulfate; product was eluted with 20% CH 3 CN.
  • Solvent was removed under vacuum from the product-containing fraction pool which was then desalted in similar fashion as in Example 5, pH adjusted to 6.3 then freeze dried. Yield: 2.7 mg of a white solid, PTC-PBP-3, C 54 H 87 N 17 O 12 S.
  • N-phenylthiocarbamyl-(NaSO 3 -Fmoc) 5 -PBP-3 was dissolved in 0.30 mL of anhydrous trifluoroacetic acid (TFA) and heated in a 50° C. water bath for 15 min. TFA was evaporated with a stream of dry nitrogen and the residue was dissolved in 12 mL 0.20M ammonium phosphate at pH7.2 and 6 mL CH 3 CN containing 49 mg triglycine (as an acylating agent scavenger).
  • TFA trifluoroacetic acid
  • the product solution was first applied to a 0.5 g styrene-divinylbenzene resin cartridge (EnviChrom-P) which was eluted with 10 mL of 40% CH 3 CN 0.04M in ammonium phosphate at pH 7.2.
  • Product-containing fractions were pooled ( ⁇ 18 mL), diluted with 12 mL distilled water, then applied to a fresh 0.5 g resin cartridge which was eluted with incrementally increasing concentrations of CH 3 CN about 0.05M in ammonium phosphate at pH 7.2.
  • reaction mixture was diluted with 4 mL 0.25M ammonium sulfate at pH2.3 yielding a very milky mixture at pH 3.0 which was extracted with 4 mL ethylacetate; the product-containing aqueous phase was diluted with 4 mL distilled water.
  • Product was initially isolated by size exclusion chromatography on a Sephadex® G-25 column (2.5 ⁇ 40 cm) eluted with 0.10M ammonium sulfate at pH 2.3.
  • reaction mixture was diluted with 5 mL 0.20M ammonium sulfate at pH2.3 yielding a very milky mixture at pH 2.8 which was extracted with 5 mL ethylacetate.
  • Product was initially isolated by size exclusion chromatography on a Sephadex® G-25 column (2.5 ⁇ 40 cm) eluted with 0.10M ammonium sulfate at pH 2.3.
  • Product-containing fractions were pooled and further purified on a 0.5 g styrene-divinylbenzene cartridge (EnviChrom-P) by elution with incrementally increasing concentrations of CH 3 CN about 0.10M in ammonium sulfate at pH 2.3; product was eluted with 30% CH 3 CN. Further purification was achieved using size exclusion chromatography on a Sephadex LH-20 column (2.5 ⁇ 40 cm) eluted with 0.026M ammonium acetate/0.053M acetic acid in MeOH. Product-containing fractions were evaporated under vacuum to near dryness, the residue dissolved in 10 mL distilled water, then desalted and freeze dried in similar fashion as in Example 5.
  • EnviChrom-P 0.5 g styrene-divinylbenzene cartridge
  • Product was further purified on a 0.5 g styrene-divinylbenzene cartridge (EnviChrom-P) using incrementally increasing concentrations of CH 3 CN about 0.05M in sodium sulfate at pH2.3; product was eluted with 25% CH 3 CN. Product-containing fractions were pooled, diluted with an equal volume of distilled water, and product was desalted and freeze dried in similar fashion as in Example 5. Yield: 4.7 mg of a white solid, Compound 7, C 59 H 90 N 16 O 14 .
  • Product was isolated on a 0.5 g styrene-divinylbenzene cartridge (EnviChrom-P) using incrementally increasing concentrations of CH 3 CN about 0.05M in sodium sulfate at pH2.3; product was eluted with 25% and 30% CH 3 CN. Product-containing fractions were pooled, solvent removed under vacuum, 2 mL 1.0M ammonium acetate pH 5.0 buffer was added, pH adjusted to 5.0 by addition of ca. 0.6 mL 1.5M NH 4 OH, and then diluted with an equal volume of MeOH. Product was isolated via CM-Sepharose chromatography as in Example 7.
  • Example 8 The procedure used in Example 8 to prepare the (NaSO 3 -Fmoc) 4 -PBP-2 from (NaSO 3 -Fmoc) 5 -PBP-3 was repeated starting with (NaSO 3 -Fmoc) 4 -PBP-2, 50 mg, to remove the threonine residue and yielding (NaSO 3 -Fmoc) 4 -PBP-1, 37 mg, as a white powder, with the expected HPLC relative retention time.
  • (NaSO 3 -Fmoc) 4 -PBP-2 (5.0 mg) was dissolved in 1.4 mL of 0.02M sodium citrate buffer (pH6.4) and 0.006M in 2-mercaptoethylamine(MEA) hydrochloride.
  • the enzyme solution was prepared by dissolving 10 units (0.9 mg) of cathepsin C (dipeptidyl aminopeptidase) (EC 3.4.14.1) in 11.0 mL of the citrate-MEA buffer. Enzyme solution (0.25 mL) was added to the peptide solution which was incubated at about 37° C. for about 24 hours. HPLC analysis indicated about 75% conversion to (NaSO 3 -Fmoc) 3 -PBP.
  • the incubated solution was diluted with 11.0 mL 0.4M pH7.2 ammonium phosphate buffer, 3.0 mL distilled water and 0.5 mL CH 3 CN.
  • the product was isolated on an ENVI-Chrom-P 0.5 g resin cartridge; product was eluted with 25% CH 3 CN, 0.05M in pH7.2 buffer.
  • product-containing fractions (accounting for about 72% of the total product) were pooled, desalted and freeze dried as in Example 8. Yield: 1.0 mg of a pale yellow solid, 87% by HPLC (215 nm area %), with the expected HPLC relative retention time for the (NaSO 3 -Fmoc) 3 -PBP.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
US10/881,160 2004-07-01 2004-07-01 Peptide antibiotics and peptide intermediates for their prepartion Pending US20060004185A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
US10/881,160 US20060004185A1 (en) 2004-07-01 2004-07-01 Peptide antibiotics and peptide intermediates for their prepartion
CNA2005800294199A CN101010336A (zh) 2004-07-01 2005-07-01 肽类抗生素和制备它们的方法
KR1020077002649A KR20070047770A (ko) 2004-07-01 2005-07-01 펩티드 항생제 및 이의 제조방법
JP2007519447A JP2008505858A (ja) 2004-07-01 2005-07-01 ペプチド抗生物質およびその製造方法
AU2005326770A AU2005326770B2 (en) 2004-07-01 2005-07-01 Peptide antibiotics and methods for making same
US11/630,847 US8889826B2 (en) 2004-07-01 2005-07-01 Peptide antibiotics and methods for making same
CA002571944A CA2571944A1 (en) 2004-07-01 2005-07-01 Peptide antibiotics and methods for making same
BRPI0512941-9A BRPI0512941A (pt) 2004-07-01 2005-07-01 antibióticos de peptìdeo e métodos para fazer os mesmos
NZ552730A NZ552730A (en) 2004-07-01 2005-07-01 Peptide antibodies and methods for making same
EP10184953A EP2332965A1 (en) 2004-07-01 2005-07-01 Peptide antibiotics and methods for making same
MXPA06015239A MXPA06015239A (es) 2004-07-01 2005-07-01 Antibioticos peptidicos y metodos para elaborarlos.
RU2007103811/04A RU2428429C2 (ru) 2004-07-01 2005-07-01 Пептидные антибиотики и способы их получения
PCT/US2005/023343 WO2006083317A2 (en) 2004-07-01 2005-07-01 Peptide antibiotics and methods for making same
NZ579261A NZ579261A (en) 2004-07-01 2005-07-01 Peptide Antibodies And Methods For Making Same
EP05856867A EP1761554A2 (en) 2004-07-01 2005-07-01 Peptide antibiotics and methods for making same
ZA200610818A ZA200610818B (en) 2004-07-01 2006-12-21 Peptide antibiotics and methods for making same
IL180458A IL180458A0 (en) 2004-07-01 2006-12-31 Peptide antibiotics and methods for making same
NO20070563A NO20070563L (no) 2004-07-01 2007-01-30 Peptidantibiotika og fremgangsmater for fremstilling derav.
RU2011115077/04A RU2011115077A (ru) 2004-07-01 2011-04-15 Пептидные антибиотики и способы их получения
JP2011168634A JP2011256189A (ja) 2004-07-01 2011-08-01 ペプチド抗生物質およびその製造方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/881,160 US20060004185A1 (en) 2004-07-01 2004-07-01 Peptide antibiotics and peptide intermediates for their prepartion

Publications (1)

Publication Number Publication Date
US20060004185A1 true US20060004185A1 (en) 2006-01-05

Family

ID=35514884

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/881,160 Pending US20060004185A1 (en) 2004-07-01 2004-07-01 Peptide antibiotics and peptide intermediates for their prepartion
US11/630,847 Expired - Fee Related US8889826B2 (en) 2004-07-01 2005-07-01 Peptide antibiotics and methods for making same

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/630,847 Expired - Fee Related US8889826B2 (en) 2004-07-01 2005-07-01 Peptide antibiotics and methods for making same

Country Status (15)

Country Link
US (2) US20060004185A1 (enrdf_load_stackoverflow)
EP (2) EP1761554A2 (enrdf_load_stackoverflow)
JP (2) JP2008505858A (enrdf_load_stackoverflow)
KR (1) KR20070047770A (enrdf_load_stackoverflow)
CN (1) CN101010336A (enrdf_load_stackoverflow)
AU (1) AU2005326770B2 (enrdf_load_stackoverflow)
BR (1) BRPI0512941A (enrdf_load_stackoverflow)
CA (1) CA2571944A1 (enrdf_load_stackoverflow)
IL (1) IL180458A0 (enrdf_load_stackoverflow)
MX (1) MXPA06015239A (enrdf_load_stackoverflow)
NO (1) NO20070563L (enrdf_load_stackoverflow)
NZ (2) NZ552730A (enrdf_load_stackoverflow)
RU (2) RU2428429C2 (enrdf_load_stackoverflow)
WO (1) WO2006083317A2 (enrdf_load_stackoverflow)
ZA (1) ZA200610818B (enrdf_load_stackoverflow)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007142611A1 (en) * 2006-06-02 2007-12-13 Biotika A.S. Method of polymyxin b recovery from fermentation broth
WO2008017734A1 (en) 2006-08-11 2008-02-14 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US20080287345A1 (en) * 2006-08-11 2008-11-20 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
WO2009098357A1 (en) * 2008-02-08 2009-08-13 Northern Antibiotics Oy Short fatty acid tail polymyxin derivatives and uses thereof
US20090215677A1 (en) * 2008-02-08 2009-08-27 Martti Sakari Vaara Polymyxin derivatives and uses thereof
US20090239792A1 (en) * 2008-02-08 2009-09-24 Martti Sakari Vaara Short fatty acid tail polymyxin derivatives and uses thereof
US20130053305A1 (en) * 2010-03-10 2013-02-28 Universidad De Barcelona Peptide compounds that can be used as antibacterial agents
US9096649B2 (en) 2008-02-08 2015-08-04 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
WO2016100578A2 (en) 2014-12-16 2016-06-23 Micurx Pharmaceuticals, Inc. Antimicrobial polymyxins for treatment of bacterial infections
EP3045469A1 (en) 2015-01-15 2016-07-20 Northern Antibiotics Oy Polymyxin derivative and uses thereof
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
EP3126376A4 (en) * 2014-04-01 2017-10-25 Monash University Polymyxin derivatives as antimicrobial compounds
US10234460B2 (en) 2013-08-26 2019-03-19 The University Of Tokyo Macrocyclic peptide, method for producing same, and screening method using macrocyclic peptide library
EP3556769A4 (en) * 2016-12-16 2021-03-03 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences POLYMYXINE DERIVATIVE, MANUFACTURING PROCESS AND APPLICATION OF IT
CN113174398A (zh) * 2021-04-22 2021-07-27 浙江工业大学 一种用于重组表达棘白菌素b脱酰基酶的表达盒及应用
WO2021150792A1 (en) 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
US11225505B2 (en) 2015-09-29 2022-01-18 Monash University Antimicrobial polymyxin derivative compounds
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US12012466B2 (en) 2015-10-27 2024-06-18 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
CN101970462B (zh) * 2008-03-14 2013-06-19 安斯泰来制药株式会社 环状化合物及其盐
CA2747995A1 (en) * 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2010130007A1 (en) * 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) * 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
WO2013072695A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
EP2679236A1 (de) 2012-06-29 2014-01-01 Zentrum für biomedizinische Technologie der Donau- Universität Krems Dosierungsanleitung für endotoxinbindende Lipopeptide
EP2999711B1 (en) 2013-05-22 2022-06-29 Spero Therapeutics, Inc. Polymyxin derivatives and their use in combination therapy together with different antibiotics
CN103396475B (zh) * 2013-08-06 2015-08-26 深圳翰宇药业股份有限公司 一种纯固相合成多肽类抗生素Colistin的方法
KR20230152779A (ko) * 2014-03-11 2023-11-03 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
CN103993059B (zh) * 2014-05-28 2016-08-17 河北圣雪大成制药有限责任公司 优化多粘芽孢杆菌发酵液中e1和e2组分比例的方法
EP3201216A1 (en) * 2014-09-29 2017-08-09 Technische Universität Darmstadt Method for peptide synthesis and apparatus for carrying out a method for solid phase synthesis of peptides
GB2530776A (en) * 2014-10-01 2016-04-06 Randox Lab Ltd Detection of polymyxins
JP7349773B2 (ja) 2014-11-26 2023-09-25 スペロ・セラピューティクス・インコーポレーテッド 化合物
JO3669B1 (ar) * 2015-01-06 2020-08-27 Ferring Bv بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين
ES2755815T3 (es) 2016-09-13 2020-04-23 Allergan Inc Composiciones de toxina de Clostridium no proteicas estabilizadas
CN106868079B (zh) * 2017-04-26 2020-12-08 山东鲁抗医药股份有限公司 发酵硫酸多粘菌素b用培养基及发酵生产硫酸多粘菌素b的方法
WO2019084628A1 (en) * 2017-11-02 2019-05-09 The University Of Queensland Peptide antibiotics
ES2971732T3 (es) 2018-06-25 2024-06-06 Spero Therapeutics Inc Compuestos
CN111410682A (zh) * 2020-04-28 2020-07-14 梯尔希（南京）药物研发有限公司 多粘菌素b相关化合物的环化制备方法
CN113215185B (zh) * 2021-04-22 2022-04-29 浙江工业大学 一种用于重组表达棘白菌素b脱酰基酶的重组基因序列

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3753970A (en) 1970-08-04 1973-08-21 Rhone Poulenc Sa Cyclopeptides derived from polymyxins and their preparation
FR2124060B1 (enrdf_load_stackoverflow) * 1971-02-02 1974-04-12 Rhone Poulenc Sa
US4091092A (en) 1976-09-20 1978-05-23 E. R. Squibb & Sons, Inc. Polymyxin F and process of producing polymyxin F
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5366734A (en) 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
DE3376424D1 (en) 1982-02-27 1988-06-01 Beecham Group Plc Antibacterial 1-normon-2-yl-heterocyclic compounds
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4399067A (en) * 1982-05-21 1983-08-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4601893A (en) 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
US4895566A (en) 1986-07-25 1990-01-23 C. R. Bard, Inc. Coating medical devices with cationic antibiotics
EP0516194A3 (en) 1986-08-07 1995-10-25 Puetter Medice Chem Pharm Pharmaceutical compositions containing cationic surfactants
US4830860A (en) 1986-10-30 1989-05-16 Pfizer Inc. Stressed polymeric device for controlled release of a substance to an ambient environment
US5755788A (en) 1987-02-19 1998-05-26 Rutgers, The State University Prosthesis and implants having liposomes bound thereto and methods of preparation
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
US5039789A (en) 1988-04-11 1991-08-13 Eli Lilly And Company A54145 cyclic peptides
US5028590A (en) 1988-04-11 1991-07-02 Eli Lilly And Company Derivatives of A54145 cyclic peptides
US5254535A (en) 1989-04-17 1993-10-19 The Children's Hospital Of Pennsylvania Composition and treatment with biologically active peptides and antibiotic
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5459237A (en) 1990-02-08 1995-10-17 Magainin Pharmaceuticals Inc. Peptide compositions and uses therefor
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5082653A (en) 1990-10-31 1992-01-21 Warner-Lambert Company Anti-plaque compositions comprising a combination of morpholinoamino alcohol and antibiotic
US5686065A (en) 1991-03-27 1997-11-11 Special Advanced Biomaterials, Inc. Topical siloxane sunscreen compositions having enhanced performance and safety
CA2107674A1 (en) 1991-04-08 1992-10-09 W. Lee Maloy Novel peptide compositions and uses therefor
WO1993005802A1 (en) 1991-09-13 1993-04-01 Magainin Pharmaceuticals Inc. Biologically active amphiphilic peptide compositions and uses therefor
TW274552B (enrdf_load_stackoverflow) 1992-05-26 1996-04-21 Hoechst Ag
US6348445B1 (en) 1992-06-01 2002-02-19 Magainin Pharmaceuticals, Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
US5283005A (en) 1992-10-08 1994-02-01 Olin Corporation Synergistic biocide combination for industrial fluids
US5424290A (en) 1992-10-26 1995-06-13 Magainin Pharmaceuticals Inc. Biologically active peptides and uses therefor
US5360788A (en) 1992-11-10 1994-11-01 Olin Corporation Personal care composition containing pyrithione and a basic lipopeptide
US5370876A (en) 1993-01-08 1994-12-06 Microbarriers Antimicrobial protective skin composition and method for protecting skin from body fluids
US5654451B1 (en) 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
CA2112776C (en) 1993-01-21 2002-11-12 Masakazu Tsuchiya Process for inhibiting activity of endotoxin
US20040023884A1 (en) 1993-03-12 2004-02-05 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5652332A (en) 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5733872A (en) 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US5635216A (en) 1993-12-16 1997-06-03 Eli Lilly And Company Microparticle compositions containing peptides, and methods for the preparation thereof
JPH09504512A (ja) 1993-08-13 1997-05-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 抗菌活性、抗マイコプラズマ活性、抗真菌類活性および除草活性を有するモン酸ａおよびｃの誘導体
US5587358A (en) 1994-05-09 1996-12-24 Asahi Kasei Kogyo Kabushiki Kaisha Potentiators of antimicrobial activity
FR2735983B1 (fr) 1995-06-29 1997-12-05 Centre Nat Rech Scient Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US20020150964A1 (en) 1995-12-19 2002-10-17 Centre National De La Recherche Scientifique Peptides for the activation of the immune system in humans and animals
US6011008A (en) 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
US6350438B1 (en) 1998-02-27 2002-02-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6350738B1 (en) 1998-03-06 2002-02-26 Brigham Young University Steroid derived antibiotics
US6767904B2 (en) 1998-03-06 2004-07-27 Bringham Young University Steroid derived antibiotics
WO2000018419A2 (en) 1998-09-25 2000-04-06 Cubist Pharmaceuticals, Inc. Methods for administration of antibiotics
IT1308180B1 (it) 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
US6515104B1 (en) 1999-06-25 2003-02-04 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing protein
US6964948B2 (en) 1999-06-25 2005-11-15 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein
CA2378868A1 (en) * 1999-07-15 2001-01-25 Eli Lilly And Company Process for deacylation of lipodepsipeptides
US6380356B1 (en) 1999-12-07 2002-04-30 Advanced Medicine, Inc. Multivalent polymyxin antibiotics
MXPA02006028A (es) 1999-12-15 2004-08-23 Cubist Pharm Inc Lipopeptidos novedosos como agentes antibacterianos.
WO2001044274A1 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
EP1240181A2 (en) 1999-12-15 2002-09-18 Cubist Pharmaceuticals, Inc. Daptomycin analogs as antibacterial agents
US7074392B1 (en) 2000-03-27 2006-07-11 Taro Pharmaceutical Industries Limited Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections
JP3292723B2 (ja) * 2000-05-26 2002-06-17 アルス電子株式会社 半導体パッケージ及びその製造方法
AU2001267181A1 (en) 2000-05-30 2001-12-11 Viridis Biotech Inc. Polyubiquitin based hydrogel and uses thereof
ES2309077T3 (es) 2000-06-30 2008-12-16 THE PROCTER & GAMBLE COMPANY Composiciones orales que comprenden agentes antimicrobianos para la prevencion de enfermedades sistemicas.
AU7893301A (en) * 2000-07-17 2002-01-30 Intrabiotics Pharmaceuticals Antimicrobial sulfonamide derivatives of lipopeptide antibiotics
US6511962B1 (en) 2000-07-17 2003-01-28 Micrologix Biotech Inc. Derivatives of laspartomycin and preparation and use thereof
DE60239316D1 (de) * 2001-01-16 2011-04-14 Univ Ramot Hybridpeptide für die behandlung von bacteraemie und sepsis
KR20030072614A (ko) 2001-01-31 2003-09-15 화이자 프로덕츠 인크. Ｐｄｅ４ 이소자임 억제제로 유용한 티아졸릴-,옥사졸릴-, 피롤릴- 및 이미다졸릴-산 아미드 유도체
NZ528607A (en) 2001-03-15 2007-11-30 Enteron Pharmaceuticals Inc Method of treating inflammatory GI disorders using topically active corticosteroids to reduce symptoms without causing the side effects associated with systemic steroid administration
CA2456323A1 (en) 2001-08-06 2003-03-06 Cubist Pharmaceuticals, Inc. Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
US6681765B2 (en) 2001-12-18 2004-01-27 Sheree H. Wen Antiviral and antibacterial respirator mask
US7345018B2 (en) 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
EP1360961A1 (en) 2002-05-07 2003-11-12 AM-Pharma B.V. Use of antimicrobial peptides for potentiating the activity of antimicrobial agents
US6767718B2 (en) * 2002-05-10 2004-07-27 Biosource Pharm, Inc. Lipodepsipeptide antibiotics and methods of preparation
AU2003259827B2 (en) 2002-08-12 2008-09-04 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
US20040037895A1 (en) 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1982772A1 (de) 2003-05-16 2008-10-22 Cinvention Ag Biokompatibel beschichtete medizinische Implantate
WO2005032470A2 (en) 2003-09-30 2005-04-14 Kohi Corporation Compositions and methods for treating burns
AU2004289287A1 (en) 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
US7364747B1 (en) 2004-02-02 2008-04-29 S.S. Steiner, Inc. Process and product for inhibiting or preventing bacterial infections
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
CA2572442A1 (fr) 2004-07-30 2006-03-09 Palumed S.A. Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
US7541046B1 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for protein drug delivery
EP1850796B1 (en) 2005-02-18 2015-12-09 The Cleveland Clinic Foundation Apparatus for replacing a cardiac valve
EP1893131A1 (en) 2005-04-20 2008-03-05 The Cleveland Clinic Foundation Apparatus and method for replacing a cardiac valve
AU2006270135A1 (en) 2005-07-15 2007-01-25 The Cleveland Clinic Foundation Apparatus and method for remodeling a cardiac valve annulus
US20070196421A1 (en) 2005-10-03 2007-08-23 Hunter William L Soft tissue implants and drug combination compositions, and use thereof
US20070208134A1 (en) 2005-10-03 2007-09-06 Hunter William L Anti-scarring drug combinations and use thereof
US20070299043A1 (en) 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
WO2007041584A2 (en) 2005-10-03 2007-04-12 Combinatorx, Incorporated Implantable sensors, implantable pumps, and anti-scarring drug combinations
KR100750658B1 (ko) 2005-12-09 2007-08-20 한국생명공학연구원 폴리믹신 생합성 효소 및 이를 코딩하는 유전자 군
US20080009902A1 (en) 2006-01-30 2008-01-10 Angiotech Pharmaceuticals, Inc. Sutures and fibrosing agents
WO2007097940A2 (en) 2006-02-13 2007-08-30 Trustees Of Boston University Reca inhibitors with antibiotic activity, compositions and methods of use
WO2007095631A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California New drug delivery system for crossing the blood brain barrier
US20070197658A1 (en) 2006-02-22 2007-08-23 David Sunil A Polyamines and their use as antibacterial and sensitizing agents
US8585753B2 (en) 2006-03-04 2013-11-19 John James Scanlon Fibrillated biodegradable prosthesis
US20070243275A1 (en) 2006-04-13 2007-10-18 Gilbard Jeffrey P Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
US8652201B2 (en) 2006-04-26 2014-02-18 The Cleveland Clinic Foundation Apparatus and method for treating cardiovascular diseases
WO2007133944A2 (en) 2006-05-09 2007-11-22 Emisphere Technologies, Inc. Topical administration of acyclovir
AU2007279442A1 (en) 2006-08-03 2008-02-07 Prosensa Technologies B.V. Antibiotic composition
JP5226685B2 (ja) 2006-08-11 2013-07-03 ノーザン アンチバイオティクス オイ ポリミキシン誘導体およびその使用
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US20100028334A1 (en) 2006-12-15 2010-02-04 Trustees Of Boston University Compositions and methods to potentiate colistin activity
JP5559031B2 (ja) 2007-04-02 2014-07-23 マウント シナイ スクール オブ メディスン 抗菌薬耐性株を含む細胞外微生物により引き起こされる感染症をガリウム化合物を用いて予防または治療する方法
US20090048155A1 (en) 2007-08-15 2009-02-19 Endacea, Inc. Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
US20090214601A1 (en) 2007-09-28 2009-08-27 Chappa Ralph A Porous Drug Delivery Devices and Related Methods
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
CA2747995A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007142611A1 (en) * 2006-06-02 2007-12-13 Biotika A.S. Method of polymyxin b recovery from fermentation broth
EP3078672A1 (en) 2006-08-11 2016-10-12 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
WO2008017734A1 (en) 2006-08-11 2008-02-14 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US20080287345A1 (en) * 2006-08-11 2008-11-20 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US9067974B2 (en) 2006-08-11 2015-06-30 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US8680234B2 (en) 2006-08-11 2014-03-25 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US20100292136A1 (en) * 2006-08-11 2010-11-18 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
JP2011511045A (ja) * 2008-02-08 2011-04-07 ノーザン アンチバイオティクス オイ 短鎖脂肪酸の尾部を有するポリミキシン誘導体およびその使用
US8642535B2 (en) 2008-02-08 2014-02-04 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
US20090239792A1 (en) * 2008-02-08 2009-09-24 Martti Sakari Vaara Short fatty acid tail polymyxin derivatives and uses thereof
US20090215677A1 (en) * 2008-02-08 2009-08-27 Martti Sakari Vaara Polymyxin derivatives and uses thereof
US9090669B2 (en) 2008-02-08 2015-07-28 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
US9096649B2 (en) 2008-02-08 2015-08-04 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
JP2015145399A (ja) * 2008-02-08 2015-08-13 ノーザン アンチバイオティクス オイ 短鎖脂肪酸の尾部を有するポリミキシン誘導体およびその使用
EP3263586A1 (en) 2008-02-08 2018-01-03 Northern Antibiotics Oy Short fatty acid tail polymyxin derivatives and uses thereof
WO2009098357A1 (en) * 2008-02-08 2009-08-13 Northern Antibiotics Oy Short fatty acid tail polymyxin derivatives and uses thereof
US20130053305A1 (en) * 2010-03-10 2013-02-28 Universidad De Barcelona Peptide compounds that can be used as antibacterial agents
US10234460B2 (en) 2013-08-26 2019-03-19 The University Of Tokyo Macrocyclic peptide, method for producing same, and screening method using macrocyclic peptide library
EP3126376A4 (en) * 2014-04-01 2017-10-25 Monash University Polymyxin derivatives as antimicrobial compounds
US10047126B2 (en) 2014-04-01 2018-08-14 Monash University Polymyxin derivatives as antimicrobial compounds
USRE48335E1 (en) 2014-04-01 2020-12-01 Monash University Polymyxin derivatives as antimicrobial compounds
WO2016100578A2 (en) 2014-12-16 2016-06-23 Micurx Pharmaceuticals, Inc. Antimicrobial polymyxins for treatment of bacterial infections
WO2016100578A3 (en) * 2014-12-16 2016-08-11 Micurx Pharmaceuticals, Inc. Antimicrobial polymyxins for treatment of bacterial infections
CN107257803A (zh) * 2014-12-16 2017-10-17 盟科医药技术公司（开曼群岛） 用于治疗细菌感染的多粘菌素类抗菌剂
KR102585108B1 (ko) * 2014-12-16 2023-10-05 상하이 미큐알엑스 파마슈티컬 컴퍼니 리미티드 세균 감염의 치료를 위한 항미생물성 폴리믹신
US9771394B2 (en) 2014-12-16 2017-09-26 Micurx Pharmaceuticals, Inc. Antimicrobial polymyxins for treatment of bacterial infections
KR20170086671A (ko) * 2014-12-16 2017-07-26 미큐알엑스 파마슈티컬스, 인코포레이티드 세균 감염의 치료를 위한 항미생물성 폴리믹신
EP3045469A1 (en) 2015-01-15 2016-07-20 Northern Antibiotics Oy Polymyxin derivative and uses thereof
WO2016113470A1 (en) 2015-01-15 2016-07-21 Northern Antibiotics Oy Polymyxin derivative and uses thereof
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
US11225505B2 (en) 2015-09-29 2022-01-18 Monash University Antimicrobial polymyxin derivative compounds
US12012466B2 (en) 2015-10-27 2024-06-18 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
EP3556769A4 (en) * 2016-12-16 2021-03-03 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences POLYMYXINE DERIVATIVE, MANUFACTURING PROCESS AND APPLICATION OF IT
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
WO2021150792A1 (en) 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
CN113174398A (zh) * 2021-04-22 2021-07-27 浙江工业大学 一种用于重组表达棘白菌素b脱酰基酶的表达盒及应用

Also Published As

Publication number Publication date
EP1761554A2 (en) 2007-03-14
CA2571944A1 (en) 2006-08-10
RU2007103811A (ru) 2008-08-10
WO2006083317A3 (en) 2007-01-18
CN101010336A (zh) 2007-08-01
WO2006083317A9 (en) 2007-03-01
BRPI0512941A (pt) 2007-10-30
IL180458A0 (en) 2007-06-03
RU2428429C2 (ru) 2011-09-10
NZ552730A (en) 2009-09-25
US20080207874A1 (en) 2008-08-28
EP2332965A1 (en) 2011-06-15
WO2006083317A2 (en) 2006-08-10
ZA200610818B (en) 2008-07-30
KR20070047770A (ko) 2007-05-07
MXPA06015239A (es) 2007-12-10
NZ579261A (en) 2011-02-25
AU2005326770B2 (en) 2011-11-03
US8889826B2 (en) 2014-11-18
RU2011115077A (ru) 2012-10-20
NO20070563L (no) 2007-03-27
AU2005326770A1 (en) 2006-08-10
JP2008505858A (ja) 2008-02-28
JP2011256189A (ja) 2011-12-22

Similar Documents

Publication Publication Date Title
US20060004185A1 (en) Peptide antibiotics and peptide intermediates for their prepartion
CA2118757C (en) Aza cyclohexapeptide compounds
BOECK et al. Deacylation of echinocandin B by Actinoplanes utahensis
CA2979273C (en) Short fatty acid tail polymyxin derivatives and uses thereof
US9090669B2 (en) Short fatty acid tail polymyxin derivatives and uses thereof
US8415307B1 (en) Antibiotic compositions for the treatment of gram negative infections
US20020035239A1 (en) Peptide antibiotics
US5516756A (en) Aza cyclohexapeptide compounds
US9096649B2 (en) Polymyxin derivatives and uses thereof
AU5168196A (en) Novel antifungal cyclohexapeptides
HU193528B (en) Process for preparing a-219780 cyclic peptide-acil derivatives
WO1994009033A1 (en) An improved process for cyclohexapeptidyl bisamine compounds
US5962407A (en) Loloatin derivatives and analogs
EP2493843A1 (en) 2-amino-3-methyl-hex-5-enoic acid and its use in the production of peptides such as bacitracins

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOSOURCE PHARM, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEESE, RICHARD A.;FRANCIS, NORMAN D.;CURRAN, WILLIAM V.;AND OTHERS;REEL/FRAME:015558/0839

Effective date: 20040629